欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

zentiva k.s. - emtritsitabiin, tenofoviirdisoproksiilfosfaat - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - ravi hiv-1 infectionemtricitabine/tenofovir disoproxil zentiva on näidustatud kombineeritud retroviirusevastast ravi ravi hiv-1 nakkusega täiskasvanutel. emtricitabine/tenofovir disoproxil zentiva on näidustatud ka ravi hiv-1 nakatunud noorukid, kellel nrti resistentsusega või mürgisus on vastuolus, kasutamine, esimene rida ained. pre-kokkupuute profülaktika (prep)emtricitabine/tenofovir disoproxil zentiva on näidustatud kombinatsioonis turvalisema seksi tavade pre-kokkupuute profülaktika riski vähendamiseks sugulisel teel omandatud hiv-1 nakkusega täiskasvanutel ja noorukitel on suur risk.

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

pharmaceutical works polpharma s.a. - gliklasiid - toimeainet modifitseeritult vabastav tablett - 30mg 56tk; 30mg 98tk; 30mg 30tk; 30mg 10tk; 30mg 90tk; 30mg 100tk; 30mg 60tk; 30mg 20tk; 30mg 28tk; 30mg 120tk

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

zaklady farmaceutyczne polpharma s.a. - nebivolool - tablett - 5mg 50tk; 5mg 100tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

zaklady farmaceutyczne polpharma s.a. - nebivolool - tablett - 10mg 50tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

amomed pharma gmbh - imatiniib - õhukese polümeerikattega tablett - 400mg 60tk; 400mg 180tk; 400mg 90tk; 400mg 120tk; 400mg 30tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

woerwag pharma gmbh & co. kg - metformiin - õhukese polümeerikattega tablett - 500mg 120tk; 500mg 30tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

tad pharma gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 15mg 28tk; 15mg 100tk; 15mg 90tk; 15mg 30tk; 15mg 60tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

tad pharma gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 20mg 60tk; 20mg 56tk; 20mg 10tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

g.l. pharma gmbh - etorikoksiib - õhukese polümeerikattega tablett - 120mg 10tk; 120mg 98tk; 120mg 14tk; 120mg 7tk; 120mg 20tk; 120mg 5tk; 120mg 2tk; 120mg 84tk; 120mg 49tk; 120mg 28tk